The miRNA pathway in neurological and skeletal muscle disease: implications for pathogenesis and therapy

被引:21
|
作者
Sibley, Christopher R. [1 ]
Wood, Matthew J. A. [1 ]
机构
[1] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3QX, England
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2011年 / 89卷 / 11期
基金
英国惠康基金;
关键词
RNAi; miRNA; Neurodegeneration; Myopathy; Muscular dystrophy; SERUM RESPONSE FACTOR; PROTEIN-DEFICIENT MICE; CENTRAL-NERVOUS-SYSTEM; PEPTIDE NUCLEIC-ACIDS; NF-KAPPA-B; ALZHEIMERS-DISEASE; IN-VIVO; MICRORNA EXPRESSION; HUNTINGTONS-DISEASE; MESSENGER-RNAS;
D O I
10.1007/s00109-011-0781-z
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
RNA interference (RNAi) represents a powerful post-transcriptional gene silencing network which fine-tunes gene expression in all eukaryotic cells. The endogenous triggers of RNAi, microRNAs (miRNAs), are proposed to regulate expression of up to a third of all protein-coding genes, and have been shown to have critical roles in developmental processes including in the central nervous system and skeletal muscle. Further, many have been reported to display differential expression in various disease states. Here we describe present understanding of the biogenesis and function of miRNAs, review current knowledge of miRNA abnormalities in both human neurological and skeletal muscle disease and discuss their potential as novel disease biomarkers. Finally, we highlight the many ways in which the miRNA pathway may be targeted for therapeutic benefit.
引用
收藏
页码:1065 / 1077
页数:13
相关论文
共 50 条
  • [1] The miRNA pathway in neurological and skeletal muscle disease: implications for pathogenesis and therapy
    Christopher R. Sibley
    Matthew J. A. Wood
    Journal of Molecular Medicine, 2011, 89 : 1065 - 1077
  • [2] Mitochondrial dynamics, quality control and miRNA regulation in skeletal muscle: implications for obesity and related metabolic disease
    Dahlmans, Dennis
    Houzelle, Alexandre
    Schrauwen, Patrick
    Hoeks, Joris
    CLINICAL SCIENCE, 2016, 130 (11) : 843 - 852
  • [3] Autophagy in skeletal muscle: implications for Pompe disease
    Shea, L.
    Raben, N.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2009, 47 : S42 - S47
  • [4] The molecular mechanisms of skeletal muscle wasting: Implications for therapy
    Skipworth, R. J. E.
    Stewart, G. D.
    Ross, J. A.
    Guttridge, D. C.
    Fearon, K. C. H.
    SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND, 2006, 4 (05): : 273 - 283
  • [5] The Notch signaling pathway in skeletal muscle health and disease
    Vargas-Franco, Dorianmarie
    Kalra, Raghav
    Draper, Isabelle
    Pacak, Christina A.
    Asakura, Atsushi
    Kang, Peter B.
    MUSCLE & NERVE, 2022, 66 (05) : 530 - 544
  • [6] MEASUREMENT, NATURE, AND IMPLICATIONS OF SKELETAL-MUSCLE STRENGTH IN PATIENTS WITH NEUROLOGICAL DISORDERS
    BOHANNON, RW
    CLINICAL BIOMECHANICS, 1995, 10 (06) : 283 - 292
  • [7] Role of β-adrenoceptor signaling in skeletal muscle:: Implications for muscle wasting and disease
    Lynch, Gordon S.
    Ryall, James G.
    PHYSIOLOGICAL REVIEWS, 2008, 88 (02) : 729 - 767
  • [8] Skeletal muscle mitophagy in chronic disease: implications for muscle oxidative capacity?
    Leermakers, Pieter A.
    Gosker, Harry R.
    CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2016, 19 (06): : 427 - 433
  • [9] Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and Therapy
    Kabbara, Khaled W.
    Cannon, Timothy
    Winer, Arthur
    Wadlow, Raymond
    ONCOLOGY-NEW YORK, 2022, 36 (08): : 492 - 498
  • [10] Gap junctions in liver disease: Implications for pathogenesis and therapy
    Hernandez-Guerra, Manuel
    Hadjihambi, Anna
    Jalan, Rajiv
    JOURNAL OF HEPATOLOGY, 2019, 70 (04) : 759 - 772